A better managed, less lazy and more strategic path over the last 20 years and the outcome could have been different. The company is now on it's knees financially and the only promising drug from a commercial perspective BIT225 raises more questions than answers... this after multiple Phase 2 trials over last decade. Big Pharma will not enter into a deal with significant questions remaining and much uncertainty... hence even more trials or next generation development.
Of course there is no appetite for another credit raising under current hopeless board to carry out even more scientific research... if there was to be one now the raise price would be sub .01 & devastating for existing holders. The only option of significant funding remains conversion of options which now look toast because the only thing left to announce is final results of HIV which MM has already stated will look no different to preliminary. Anything else regarding future trials, cancer treatments and further COVID trials are all pie in the sky.
BIT-225 could well be worth a considerable sum and the current board has had 20 years to prove it.. There has been a failue somewhere to now be sitting at 1.7cents SP... is it the drug that has failed, management or both?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)